{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological+Control&page=27",
    "query": {
      "intervention": "Biological Control",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 1573,
    "total_pages": 158,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological+Control&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological+Control&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T20:15:29.491Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04740671",
      "title": "A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "HLX04-O",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanghai Henlius Biotech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 410,
      "start_date": "2021-07-01",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-01-03",
      "last_synced_at": "2026-10-24T20:15:29.491Z",
      "location_count": 42,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Fullerton, California + 34 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04740671"
    },
    {
      "nct_id": "NCT02112045",
      "title": "A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Granix",
          "type": "DRUG"
        },
        {
          "name": "High dose melphalan (HDR)",
          "type": "DRUG"
        },
        {
          "name": "Autologous Stem Cell Transplant (ASCT)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2015-01-20",
      "completion_date": "2019-09-10",
      "has_results": true,
      "last_update_posted_date": "2019-11-26",
      "last_synced_at": "2026-10-24T20:15:29.491Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02112045"
    },
    {
      "nct_id": "NCT05516472",
      "title": "Fecal Microbiota Transplantation in Kidney Stone Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Kidney Stones"
      ],
      "interventions": [
        {
          "name": "Microbial Transplant Therapy",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Joshua Stern",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 36,
      "start_date": "2024-10-10",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2025-03-10",
      "last_synced_at": "2026-10-24T20:15:29.491Z",
      "location_count": 1,
      "location_summary": "Park City, Utah",
      "locations": [
        {
          "city": "Park City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05516472"
    },
    {
      "nct_id": "NCT05295719",
      "title": "Combining HIIT and n-3 PUFA to Reduce Inflammation and Improve Metabolic Health",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Inflammation",
        "Human Microbiome",
        "Insulin Resistance",
        "Dyslipidemias"
      ],
      "interventions": [
        {
          "name": "Omega-3 polyunsaturated fatty acid",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "High-Intensity Interval Training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Safflower oil",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Low-intensity training",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "BEHAVIORAL"
      ],
      "sponsor": "Texas Tech University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 129,
      "start_date": "2022-09-01",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-09-11",
      "last_synced_at": "2026-10-24T20:15:29.491Z",
      "location_count": 1,
      "location_summary": "Lubbock, Texas",
      "locations": [
        {
          "city": "Lubbock",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05295719"
    },
    {
      "nct_id": "NCT01903330",
      "title": "ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "ERC1671",
          "type": "DRUG"
        },
        {
          "name": "GM-CSF",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Oral Control (Sucrose pill)",
          "type": "DRUG"
        },
        {
          "name": "Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab/Bevacizumab Biosimilar",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Epitopoietic Research Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2014-03",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2025-03-05",
      "last_synced_at": "2026-10-24T20:15:29.491Z",
      "location_count": 3,
      "location_summary": "Orange, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01903330"
    },
    {
      "nct_id": "NCT03719092",
      "title": "High Dose Vitamin A in Preventing Gastrointestinal GVHD in Participants Undergoing Donor Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Allogeneic Hematopoietic Stem Cell Transplantation Recipient"
      ],
      "interventions": [
        {
          "name": "Vitamin A Compound",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Best Practice",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2020-02-07",
      "completion_date": "2025-10-19",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-24T20:15:29.491Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03719092"
    },
    {
      "nct_id": "NCT07202000",
      "title": "EXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure With Preserved Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "Activin ligand-trap biological therapy",
          "type": "DRUG"
        },
        {
          "name": "Placebo, Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2026-06-03",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-10-24T20:15:29.491Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07202000"
    },
    {
      "nct_id": "NCT06113016",
      "title": "Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8",
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Early Stage Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Educational Intervention",
          "type": "OTHER"
        },
        {
          "name": "Exercise Intervention",
          "type": "OTHER"
        },
        {
          "name": "Fisetin",
          "type": "DRUG"
        },
        {
          "name": "Physical Performance Testing",
          "type": "OTHER"
        },
        {
          "name": "Placebo Administration",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 164,
      "start_date": "2024-07-23",
      "completion_date": "2031-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-10-24T20:15:29.491Z",
      "location_count": 6,
      "location_summary": "Alhambra, California • Beverly Hills, California • Burbank, California + 3 more",
      "locations": [
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Marina del Rey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06113016"
    },
    {
      "nct_id": "NCT00089492",
      "title": "A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Optimized Background ARVs",
          "type": "DRUG"
        },
        {
          "name": "enfuvirtide [Fuzeon]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2004-07",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-10-24T20:15:29.491Z",
      "location_count": 21,
      "location_summary": "Hobson City, Alabama • Fountain Valley, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Hobson City",
          "state": "Alabama"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00089492"
    },
    {
      "nct_id": "NCT05903404",
      "title": "PCOS Indirect and Intangible Economic Burden",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Polycystic Ovary Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "PCOS Challenge: The National Polycystic Ovary Syndrome Association",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 80 Years · Female only"
      },
      "enrollment_count": 1000,
      "start_date": "2022-06-22",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-06-15",
      "last_synced_at": "2026-10-24T20:15:29.491Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05903404"
    }
  ]
}